Inclusion Criteria:

          -  Eastern Collaborative Oncology Group (ECOG) performance score of less than or equal to
             2.

          -  Documented relapsed or progressive Multiple Myeloma (MM) on or after any regimen or is
             refractory to the most recent line of therapy.

          -  Positive for translocation t(11;14) as determined by an analytically validated
             Fluorescent In Situ Hybridization (FISH) assay per central laboratory testing.

          -  Received prior treatment with at least 1 prior line of therapy for MM.

          -  Measurable disease on Screening per International Myeloma Working Group (IMWG)
             criteria.

          -  Meets absolute neutrophil count, platelet count, hemoglobin, liver and kidney function
             laboratory values within 2 weeks prior to first dose of study drug.

        Exclusion Criteria:

          -  Has a pre-existing condition that is contraindicated including.

               -  Non-secretory or oligo-secretory MM

               -  Active plasma cell leukemia.

               -  Waldenström's macroglobulinemia.

               -  Primary amyloidosis.

               -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein,
                  and skin changes).

               -  Active hepatitis B or C infection based on screening blood testing.

               -  Known active Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
                  infection.

               -  Significant cardiovascular disease.

               -  Major surgery within 4 weeks prior to first dose.

               -  Acute infections requiring antibiotic, antifungal or antiviral therapy within14
                  days prior to first dose.

               -  Peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to
                  first dose.

               -  Uncontrolled diabetes or uncontrolled hypertension within 14 days prior to first
                  dose.

               -  Any other medical condition that, in the opinion of the Investigator, would
                  adversely affect the participant's participation in the study.

          -  History of other active malignancies, including myelodysplastic syndrome (MDS), within
             the past 3 years prior to study entry Other protocol defined inclusion/exclusion
             criteria could apply